When we are still embryos, proteins of the so-called “hedgehog” signaling pathway stimulate our cells to develop into different organs.
When we are adults, this pathway falls largely silent, except in certain tissues that constantly regenerate themselves, for example our skin, and the linings of our blood vessels and digestive tract.
Unfortunately, several types of cancer cells are able to reawaken this dormant pathway, causing surrounding healthy cells to produce growth factors (proteins or hormones that stimulate cell growth) that help the cancer cells proliferate and metastasize.
A potent remedy to the problem may be on its way. In a paper published in the Journal of the American Chemical Society, researchers in the laboratory of Rudi Fasan, an associate professor of chemistry at the University of Rochester, describe the development of a cyclic peptide that is able to block the activation of the pathway in live cells.
The next step will be to further optimize the peptide for increased potency, then proceed to animal trials.
The pathway is activated when a ligand (binding molecule) produced by cancer cells interacts with a receptor on the surface of healthy cells, triggering the production of growth factors. The first drug directed against this pathway was approved by the FDA in 2012, but according to Fasan, recent studies have shown that cancer cells become quickly resistant to it.
The cyclic peptide developed in Fasan’s lab blocks the ligand farther “upstream” in the pathway, utilizing a different mode of inhibition compared to the FDA-approved drug. “It is important to have different weapons against this pathway,” Fasan says, “and we have targeted a key component of it.” He adds that the compound is unlikely to develop resistance since it does not target a protein located on cancer cells.
The researchers initially designed a cyclic peptide that mimics a native protein inhibitor of the hedgehog ligand. The researchers then used bacteria to quickly produce and screen large “libraries” of variations of this peptide, from which compounds with improved activity against the cancer ligand could be isolated.
The risk, as in any chemotherapy, is that the drug candidate Fasan’s lab is developing will also inhibit the pathway in healthy skin, blood vessel, and digestive tract tissues that rely on the pathway for normal regeneration. However, the fact that a hedgehog pathway inhibitor was recently approved for use in cancer therapy holds promise that these risks are outweighed by the benefits of inhibiting cancer growth, Fasan says.
The Latest on: Cancer cell growth
- Study reveals the effect of ancestry on molecular makeup of canceron May 11, 2020 at 7:01 pm
Questions about the genealogical imprint of tumors have hovered over cancer research since the completion of the Human Genome Project in 2003.
- Growing Number of Patients Suffering From Neurological Disorder to Support the Growth of Global Autologous Cell Therapy Market, TMRon May 11, 2020 at 4:44 pm
As a result of growing pandemic of COVID-19, the pharmaceutical industry is investing a major amount in research and development of an effective vaccine that can help the doctors to save lives and ...
- Researchers identify checkpoint target for colorectal cancer immunotherapyon May 11, 2020 at 11:29 am
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.
- Cancer-eating immune cells kitted out with CARson May 11, 2020 at 8:37 am
The scientific founders of Carisma Therapeutics, a startup aiming to equip phagocytes with a chimeric antigen receptor (CAR), reported in March that their engineered macrophages could infiltrate solid ...
- HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatmenton May 11, 2020 at 8:30 am
A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the ...
- Stromal reactivity differentially drives tumour cell evolution and prostate cancer progressionon May 11, 2020 at 8:16 am
A mathematical model that integrates biological and clinical data shows that the ecology of the stroma is an important determinant of tumour evolution in prostate cancer.
- Mapping the cancer connectionon May 11, 2020 at 8:00 am
A new study takes the most comprehensive look to date at the connection between the ancestry and the molecular makeup of cancer.
- AllianceRx Walgreens Prime studies the use of cyclin-dependent kinase 4/6 inhibitors in breast cancer patientson May 11, 2020 at 6:00 am
PRNewswire/ -- A recent study of metastatic breast cancer (MBC) patients, prescribed a class of drugs that interrupt malignant cell growth, revealed ...
- Non-Small Cell Lung Cancer (NSCLC) Market Insights and Epidemiology 2017-2030 - ResearchAndMarkets.comon May 11, 2020 at 5:14 am
The "Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...
- Killing 'sleeper cells' may enhance breast cancer therapyon May 7, 2020 at 6:56 am
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer - the most common form of breast cancer in Australia - according to preclinical ...
via Google News and Bing News